Survival analysis of patients with stage IB to IIA2 Cervical Cancer: A five-year single institution review
- Author:
Zelda Sue C. De Leon
1
;
Benjamin D. Cuenca
1
Author Information
- Publication Type:Journal Article
- Keywords: Early stage; Overall survival; chemoradiation
- MeSH: Uterine Cervical Neoplasms; Disease-Free Survival; Hysterectomy; Chemotherapy, Adjuvant; Neoadjuvant Therapy
- From: Philippine Journal of Obstetrics and Gynecology 2019;43(2):34-41
- CountryPhilippines
- Language:English
-
Abstract:
Objective:This study aims to determine the disease-free survival and overall survival outcome of patients with IB to
IIA cervical cancer managed with surgery, chemoradiation, or a combination of both in a tertiary government training hospital.
Methodology:This is a retrospective study of patients diagnosed with stage IB-IIA2 cervical cancer from January 2013 to June 2017. Data were encoded using Microsoft Excel. Statistical analyses were computed using SPSS. Cox regression and Kaplan Meier analyses were used to predict survival outcomes.
Results:Out of 135 patients were included in the study, 111 received treatment. 61 had no evidence of disease. Median age is 46 years with stage IB1 disease. Majority of patients underwent surgery followed by adjuvant therapy. Tumor recurrence was highest in the surgery alone group, with median time to recurrence of 19 months. Median follow-up time was 10 months. Overall 5-year survival is 51.4%; 5-year disease-free survival is 54.8%.
Conclusions:Age is a statistically significant factor in survival. Surgery with adjuvant chemotherapy + radiation had the most favorable survival outcome. Neoadjuvant treatment gave the least number of recurrences. Despite a small sample size, this study provides baseline data into the survival outcome of patients with locally advanced cervical cancer in our institution given the different treatment recommendations. - Full text:survival-analysis-of-patients-with-stage-ib-to-iia-cervical-cancer.pdf
